Cookies & Privacy

We use essential cookies to make our site work. With your permission, we’ll also use analytics and marketing cookies to improve your experience. You can change your choice anytime.

See our Privacy Policy for details.

Manage preferences
Back to Industry News
Medtech

Gradientech's Quickmic Sepsis Test System Secures Key European IVDR Certification

Summary generated with AI, editor-reviewed
Heartspace News Desk
Source: Medtech Magazine
medtech related image for: Gradientech's Quickmic Sepsis Test System Secures Key European IVDR Certification

Photo by CDC on Unsplash

TL;DR

Gradientech's Quickmic® system, including its Quickmic® GN AST test, is now IVDR-certified and CE-marked for commercial use in the EU. This regulatory approval allows the ultra-fast antibiotic resistance test for sepsis samples to expand throughout the European market. Gradientech has achieved certification for its Quickmic® system under the European Union's In Vitro Diagnostic Regulation (IVDR). This certification covers the complete Quickmic® system, including the Quickmic® GN AST test for gram-negative bacteria and its diagnostic platform, granting it CE-marking for commercial use within the European market. According to CEO Sara Thorslund,.

Key takeaways

  • Gradientech has achieved certification for its Quickmic® system under the European Union's In Vitro Diagnostic Regulation (IVDR)
  • This certification covers the complete Quickmic® system, including the Quickmic® GN AST test for gram-negative bacteria and its diagnostic platform, granting it CE-marking for commercial use within the European market
  • According to CEO Sara Thorslund, this IVDR certification represents a significant commercial milestone for Gradientech
Gradientech has achieved certification for its Quickmic® system under the European Union's In Vitro Diagnostic Regulation (IVDR). This certification covers the complete Quickmic® system, including the Quickmic® GN AST test for gram-negative bacteria and its diagnostic platform, granting it CE-marking for commercial use within the European market. According to CEO Sara Thorslund, this IVDR certification represents a significant commercial milestone for Gradientech. The regulatory approval is a crucial step in the commercialization of Quickmic®, a rapid diagnostic tool designed for the ultra-fast determination of antibiotic resistance in sepsis samples, and, as reported by Medtech Magazine, facilitates market expansion.

Related Topics

GradientechQuickmicIVDR CertificationSepsisAntibiotic ResistanceMedical Technology

Verified mention available

Free to claim

Is this your company?

Set up real-time alerts and keep your Heartspace News coverage accurate. Verified teams can update profiles, request corrections, and collaborate on future stories.

Set up alerts Takes under 1 minute • Verified manually

Share Your Thoughts

(0 comments)

Be the first to share your thoughts on this article!

Stay Updated

Create alertsRead original